Lipidon Analytics is a bioanalytical service company established as a spin-off enterprise from the University of Zürich.
Drawing on many years of cutting edge lipid research development experience we aim to offer the best customer-oriented lipidomics analytical service in Europe specializing in identification and development of novel biomarkers for life sciences, cosmetic and food industries.
Our enterprise builds on a proprietary mass spectrometry-based technology that provides an unparalleled bioanalytical research service for the identification and quantification of metabolites in a wide range of samples ranging from humans, animals and plants to food and cosmetic products. As such Lipidon can identify value-added small molecules (metabolites) to guide and assist customer decisions ranging from personal food and cosmetic choices up to disease/therapy evaluations, and personalized medicine opportunities.
Lipidon’s modular mass spectrometry workflows can help cosmetics companies to detect novel molecules in different cosmetic preparations, thereby addressing different market segments.
Lipidon analytics adds another layer to the personalized medicine dimension of drug discovery and development pipelines.
Our technology can help the whole spectrum of food industries by characterizing the special compositions of different food products and mixtures.
Lipidon’s passion for academic research is encoded in its DNA and therefore we understand the unique needs of academic research labs.
Chief Executive Officer
Has a PhD in Biochemistry from ETH Zurich, Switzerland. He is currently assistant professor and head of the lipidomics facility at the Institute of Clinical Chemistry, University Zürich. He then worked as a postdoctoral fellow at the University of Potsdam, Germany, before returning to the ETH Zurich. In 2002 he joined the Institute of Clinical Chemistry at the University Hospital Zurich as a group leader, where he researched sphingolipid metabolism and lipidomics. Since 2014 Thorsten Hornemann is an assistant professorship in the same institute where he continues to explore lipid metabolism at the interface of translational biochemistry.
Chief Scientific Officer
Has a medical degree from Cairo University as well as PhD in Biochemistry (MD/PhD), the latter gained from University of Zürich, Institute of Clinical Chemistry. During his PhD and post-doctoral training, Dr. Othman applied different lipidomics approaches to detect novel biomarkers in cardiometabolic diseases, discover novel lipids and published over 30 publications including some in Diabetes and PNAS. Over the last three years, Dr. Othman established and directed a metabolomics and lipidomics service facility at the University of Lübeck where he helped discover several lipid and metabolite biomarkers in cardiovascular and metabolic diseases as well as cancer.
Chief Marketing Officer
Lara Ogunshola has a PhD in molecular neuroscience from University of Sussex, UK. After carrying out a postdoc in pathology at Yale University School of Medicine, USA she returned to Europe to join the Institute of Human Physiology. She later moved to the Institute of Veterinary Physiology at University of Zürich as group leader studying hypoxia mediated mechanisms of disease. She is now principle investigator and senior researcher at the Institute of Veterinary Physiology, University of Zürich. Her academic research work focuses on physiological and pathological brain vascular function and metabolism.